welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Microlin Bio to Acquire Nucleic Acid Therapeutic Assets of Marina Biotech
Microlin Bio, Inc., a development stage biotechnology company focused on the development of microRNA based therapeutics for cancer, and Marina Biotech, Inc., a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced that the companies have executed a term sheet under which Microlin intends to acquire Marina’s nucleic acid therapeutics assets.
expertly curated content related to this topic
- #FAPAwarenessFAP hashtag for the community...
- Lahey Hospital and Medical CenterLahey Hospital & Medical Center is a...
- Cancer Prevention Pharmaceuticals, Inc. and Tillotts Pharma AG Sign Licensing Agreement for CPP-1X/sulindac in Europ...Cancer Prevention Pharmaceuticals, Inc. ...
- Maude L. Blundell, MSGenetic CounselorEducation:Bache...
- Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPAThis purpose of this study is to investi...
- I Am A Visitor In Your World | Trailerhttps://vimeo.com/8230742...
- Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal CancersPrimary Objective: - To determine whethe...
English
Portuguese